[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_2377",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_2377"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB00108"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "tysabri is an integrin receptor antagonist indicated for treatment of multiple sclerosis ms tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri 1 1 5 1 crohn s disease cd tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnf a 1 2 important limitations in cd tysabri should not be used in combination with immunosuppressants or inhibitors of tnf a 1 2 tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis tysabri increases the risk of pml when initiating and continuing treatment with tysabri physicians should consider whether the expected benefit of tysabri is sufficient to offset this risk see important information regarding the risk of pml with tysabri see warnings and precautions 5 1 tysabri is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active crohn s disease with evidence of inflammation who have had an inadequate response to or are unable to tolerate conventional cd therapies and inhibitors of tnf a tysabri should not be used in combination with immunosuppressants e g 6 mercaptopurine azathioprine cyclosporine or methotrexate or inhibitors of tnf a see warnings and precautions 5 1"
    } ],
    "https://w3id.org/biolink/vocab/association_type" : [ {
      "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation"
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/TreatmentIndication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB00108",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-07-03T15:13:05.636+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "Ybo5naNNuodmPHxEiH+7ce12zhztxiN+LgdRRPGU4Ozccij6MJANLZQ7exrPZxkZB/5I4ce6KQwK1GZ9/qzQHSMQXRNVS5IOfImoF9FkkGbs5qJx7TJpMBhOxdpqu0nGKRLGUdaB6yokD+ybGnZN6FG6JKm+RNKlOcILXs5rHNI="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAVs_AYsMQtw4VmqPVH-vR_akmoYVsh9M8UJtik6UVgoE#pubinfo"
} ]